TF and chronic myelogenous leukemia, BCR-ABL1 positive: In our study, we proved that Ab@Tf-Cou6-PLGA NPs treatment can effectively suppress the proliferation and promote apoptosis of both Imatinib sensitive and resistant CML cells, illustrating that Ab@Tf-Cou6-PLGA NPs achieved excellent anti-oncogenesis efficacy in vitro (Fig. 4).